H.C. Wainwright analyst Mitchell Kapoor downgraded Carisma Therapeutics (CARM) to Neutral from Buy without a price target after the company said it would be discontinuing development of its lead program, CT-0525. The firm awaits more strategic updates and clinical data before becoming more positive on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma investors should ‘stay the course,’ says D. Boral Capital
- Carisma Therapeutics downgraded to Neutral from Outperform at Baird
- Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Carisma Therapeutics downgraded to Neutral from Buy at BTIG
- Carisma Therapeutics price target lowered to $12 from $24 at D. Boral Capital